EAM
KRYS icon

EFG Asset Management’s Krystal Biotech KRYS Stock Holding History

EFG Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$4.78M Buy
27,095
+4,217
+18% +$631K 0.62% 61
2025
Q2 		$3.14M Buy
22,878
+5,507
+32% +$809K 0.44% 98
2025
Q1 		$3.13M Sell
17,371
-343
-2% -$57.7K 0.52% 65
2024
Q4 		$2.78M Buy
17,714
+4,185
+31% +$742K 0.38% 111
2024
Q3 		$2.46M Buy
13,529
+974
+8% +$188K 0.41% 101
2024
Q2 		$2.31M Buy
12,555
+60
+0.5% +$10.1K 0.4% 95
2024
Q1 		$2.22M Buy
12,495
+2,299
+23% +$319K 0.38% 103
2023
Q4 		$1.26M Sell
10,196
-6,038
-37% -$670K 0.24% 154
2023
Q3 		$1.88M Sell
16,234
-1,550
-9% -$189K 0.45% 73
2023
Q2 		$2.09M Sell
17,784
-3,065
-15% -$313K 0.45% 70
2023
Q1 		$1.67M Sell
20,849
-1,167
-5% -$91.7K 0.37% 94
2022
Q4 		$1.76M Buy
22,016
+4,315
+24% +$320K 0.4% 90
2022
Q3 		$1.23M Buy
+17,701
New +$1.28M 0.28% 118

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EFG Asset Management's KRYS Position: Q3 2025 in Review

EFG Asset Management increased its Krystal Biotech (KRYS) stake by 18% in Q3 2025, buying an estimated $631K and bringing the position to 27,095 shares worth $4.78M. The position accounts for 0.62% of the portfolio, ranked #61.

EFG Asset Management first reported a position in KRYS in Q3 2022 and has held it in 13 quarters since. 284 funds tracked by Wall St. Rank hold KRYS as of Q3 2025.

  • EFG Asset Management held 27,095 shares of Krystal Biotech worth $4.78M as of Q3 2025.
  • EFG Asset Management bought 4,217 Krystal Biotech shares in Q3 2025, an estimated $631K.
  • Krystal Biotech made up 0.62% of EFG Asset Management's portfolio in Q3 2025, its #61 holding.
  • EFG Asset Management first reported a position in Krystal Biotech in Q3 2022 and has held it in 13 quarters since.
  • 284 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2025.

Based on EFG Asset Management's 13F filing for Q3 2025, filed 3 Nov 2025.